Prelude Therapeutics Set to Shine at Upcoming Conference

Author: Ryan Hughes Updated: 05-01-2025 07:38 AM

Prelude Therapeutics to Join Citizens Life Sciences Conference

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company based in Wilmington, Delaware, has exciting news. The company will participate in the Citizens Life Sciences Conference in New York, showcasing its commitment to advancing oncology treatments.

Conference Participation Details

The much-anticipated event will take place on May 7, 2025, marking a significant opportunity for Prelude. Leading the discussions will be Kris Vaddi, Ph.D., the Chief Executive Officer; Jane Huang, M.D., the President and Chief Medical Officer; and Peggy Scherle, Ph.D., the Chief Scientific Officer. They will engage in a fireside chat starting at 11:00 a.m. ET, offering insights into the company’s progress and future directions.

Accessing the Live Webcast

For those unable to attend in person, a live webcast of the session will be available via the company’s website under the Events and Presentations section. Following the event, Prelude will archive the recording for 90 days, allowing stakeholders to revisit their discussion and insights.

About Prelude Therapeutics

Prelude Therapeutics prides itself on being a leader in precision oncology, focusing on solutions for patients with significant unmet medical needs. Their research and development efforts are directed at innovative medicine, including first-in-class SMARCA2 degraders for both intravenous and oral administration, alongside a promising CDK9 inhibitor. Moreover, they are pioneering next-generation degrader antibody conjugates (Precision ADCs) through collaborations with various partners.

Commitment to Cancer Patients

The company’s mission is clear: to enhance the prospects of precision medicine for every cancer patient in need. Their comprehensive pipeline stands testament to their dedication to fighting cancer with innovative strategies targeting the complexities of this disease.

Investor Relations Information

Prelude Therapeutics encourages interested parties to reach out for further information regarding their developments and initiatives. They can contact Robert Doody, the Senior Vice President of Investor Relations, at 484.639.7235 or via email at RDoody@preludetx.com. Prelude welcomes all inquiries from investors and stakeholders eager to learn more about their impactful work.

Frequently Asked Questions

What is the focus of Prelude Therapeutics?

Prelude Therapeutics focuses on developing innovative precision oncology medications for cancer patients, addressing significant unmet medical needs.

When will Prelude participate in the conference?

Prelude will participate in the Citizens Life Sciences Conference on May 7, 2025, with activities beginning at 11:00 a.m. ET.

Who will represent Prelude at the conference?

The company will be represented by Kris Vaddi, Jane Huang, and Peggy Scherle during the fireside chat.

How can I access the webcast?

The live webcast can be accessed on Prelude's website under Events and Presentations, with recordings available for 90 days post-event.

How can I contact Prelude for investor inquiries?

Robert Doody, Senior VP of Investor Relations, is available at 484.639.7235 or via email at RDoody@preludetx.com for any investor questions or requests.

About The Author

Hello, my name is Ryan Hughes. I am a financial, economics, and stock market specialist committed to assisting people in negotiating the intricacies of the financial system. Having a great deal of experience and a thorough grasp of market dynamics and economic trends, my area of expertise is converting complex financial ideas into understandable, practical knowledge. By use of my articles and blog entries, I hope to give you the information and assurance you need to make wise financial choices.

I've had the honor of interacting with a wide range of readers as a writer for several financial blogs, from new investors to seasoned market participants. To enable you to reach your financial goals, I want to make finance, economics, and stock market trends understandable and approachable. I appreciate you traveling with me toward success and financial literacy.

Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.